UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 446

Sortiert nach

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Nature Medicine, 2019-05, Vol.25 (5), p.751-758

2019

Volltextzugriff (PDF)

Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge

Journal of the American College of Surgeons, 2017-01, Vol.224 (1), p.1-7

Schilsky, Richard L., MD, FACP, FASCO

2017

Volltextzugriff (PDF)

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3817-3825

2015

Volltextzugriff (PDF)

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Journal of clinical oncology, 2016-01, Vol.34 (2), p.179-185

2016

Volltextzugriff (PDF)

‘Strategic’ development of precision cancer medicine in the United States

Molecular oncology, 2021-07, Vol.15 (7), p.1747-1749

Schilsky, Richard L.

2021

Volltextzugriff (PDF)

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

Journal of clinical oncology, 2016-08, Vol.34 (24), p.2925-2934

2016

Volltextzugriff (PDF)

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

Journal of clinical oncology, 2015-08, Vol.33 (23), p.2563-2577

2015

Volltextzugriff (PDF)

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Journal of clinical oncology, 2017-11, Vol.35 (33), p.3737-3744

2017

Volltextzugriff (PDF)

American Society of Clinical Oncology Statement: Biosimilars in Oncology

Journal of clinical oncology, 2018-04, Vol.36 (12), p.1260-1265

2018

Volltextzugriff (PDF)

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

JNCI : Journal of the National Cancer Institute, 2015-11, Vol.107 (11), p.djv253

2015

Volltextzugriff (PDF)

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3617-3622

2010

Volltextzugriff (PDF)

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Journal of clinical oncology, 2018-04, Vol.36 (10), p.1020-1044

2018

Volltextzugriff (PDF)

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Journal of clinical oncology, 2009-04, Vol.27 (12), p.2091-2096

2009

Volltextzugriff (PDF)

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Journal of clinical oncology, 2008-11, Vol.26 (31), p.5043-5051

2008

Volltextzugriff (PDF)

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

JCO oncology practice, 2020-07, Vol.16 (7), p.417-421

2020

Volltextzugriff (PDF)

The International Collaboration for Cancer Classification and Research

International journal of cancer, 2021-02, Vol.148 (3), p.560-571

2021

Volltextzugriff (PDF)

Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1134-1139

2013

Volltextzugriff (PDF)

Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1775-1781

2013

Volltextzugriff (PDF)

Personalized medicine in oncology: the future is now

Nature reviews. Drug discovery, 2010-05, Vol.9 (5), p.363-366

Schilsky, Richard L

2010

Volltextzugriff (PDF)

Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Journal of clinical oncology, 2006-08, Vol.24 (22), p.3535-3541

2006

Volltextzugriff (PDF)

Progress against GI cancer during the American Society of Clinical Oncology's first 50 years

Journal of clinical oncology, 2014-05, Vol.32 (15), p.1521-1530

2014

Volltextzugriff (PDF)

Modernizing Eligibility Criteria for Molecularly Driven Trials

Journal of clinical oncology, 2015-09, Vol.33 (25), p.2815-2820

2015

Volltextzugriff (PDF)

Clinical trials in the era of personalized oncology

CA: a cancer journal for clinicians, 2011-11, Vol.61 (6), p.365-381

2011

Volltextzugriff (PDF)

Breaking a vicious cycle

Science translational medicine, 2013-07, Vol.5 (196), p.196cm6

2013

Volltextzugriff (PDF)

Implementing personalized cancer care

Nature reviews. Clinical oncology, 2014-07, Vol.11 (7), p.432-438

Schilsky, Richard L

2014

Volltextzugriff (PDF)

1 – 25 von 446

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(431)
Mit Volltextzugriff
(390)

Publikationsform

Sprache

Englisch
(446)
Japanisch
(42)

Erscheinungsjahr

n.n

Thema

Science & Technology
(299)
Life Sciences & Biomedicine
(296)
Humans
(291)
Oncology
(252)
Female
(117)
Biological And Medical Sciences
(116)
Medical Sciences
(116)
Male
(99)
Aged
(94)
Middle Aged
(94)
Adult
(82)
Pharmacology. Drug Treatments
(82)
Antineoplastic Agents
(79)
Neoplasms - Drug Therapy
(71)
Tumors
(70)
Chemotherapy
(58)
United States
(56)
Neoplasms - Therapy
(51)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(46)
Cancer
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

‘Strategic’ development of precision cancer medicine in the United States

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

American Society of Clinical Oncology Statement: Biosimilars in Oncology

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey

The International Collaboration for Cancer Classification and Research

Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists

Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581

Personalized medicine in oncology: the future is now

Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803

Progress against GI cancer during the American Society of Clinical Oncology's first 50 years

Modernizing Eligibility Criteria for Molecularly Driven Trials

Clinical trials in the era of personalized oncology

Breaking a vicious cycle

Implementing personalized cancer care

Suchergebnisse filtern